Clinical and Translational Allergy (Dec 2021)
Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis
- Ivan Cherrez‐Ojeda,
- Emanuel Vanegas,
- Annia Cherrez,
- Miguel Felix,
- Karsten Weller,
- Markus Magerl,
- Rasmus Robin Maurer,
- Valeria L. Mata,
- Alicja Kasperska‐Zajac,
- Agnieszka Sikora,
- Daria Fomina,
- Elena Kovalkova,
- Kiran Godse,
- Nimmagadda Dheeraj Rao,
- Maryam Khoshkhui,
- Sahar Rastgoo,
- Roberta F. J. Criado,
- Mohamed Abuzakouk,
- Deepa Grandon,
- Martijn B. A. Van Doorn,
- Solange Oliveira Rodrigues Valle,
- Eduardo Magalhães De Souza Lima,
- Simon Francis Thomsen,
- German D. Ramón,
- Edgar E. Matos Benavides,
- Andrea Bauer,
- Ana M. Giménez‐Arnau,
- Emek Kocatürk,
- Carole Guillet,
- Jose Ignacio Larco,
- Zuo‐Tao Zhao,
- Michael Makris,
- Carla Ritchie,
- Paraskevi Xepapadaki,
- Luis Felipe Ensina,
- Sofia Cherrez,
- Marcus Maurer
Affiliations
- Ivan Cherrez‐Ojeda
- Universidad Espíritu Santo Samborondón Ecuador
- Emanuel Vanegas
- Universidad Espíritu Santo Samborondón Ecuador
- Annia Cherrez
- Respiralab Respiralab Research Group Guayaquil Ecuador
- Miguel Felix
- Universidad Espíritu Santo Samborondón Ecuador
- Karsten Weller
- Institute for Allergology, Charité ‐ Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany
- Markus Magerl
- Institute for Allergology, Charité ‐ Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany
- Rasmus Robin Maurer
- Institute for Allergology, Charité ‐ Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany
- Valeria L. Mata
- Universidad Espíritu Santo Samborondón Ecuador
- Alicja Kasperska‐Zajac
- European Center for Diagnosis and Treatment of Urticaria Medical University of Silesia Katowice Poland
- Agnieszka Sikora
- European Center for Diagnosis and Treatment of Urticaria Medical University of Silesia Katowice Poland
- Daria Fomina
- City Center of Allergy and Immunology Clinical City Hospital #52 Moscow Russia
- Elena Kovalkova
- City Center of Allergy and Immunology Clinical City Hospital #52 Moscow Russia
- Kiran Godse
- Department of Dermatology D Y, Patil University School of Medicine and Hospital Mumbai India
- Nimmagadda Dheeraj Rao
- Department of Dermatology D Y, Patil University School of Medicine and Hospital Mumbai India
- Maryam Khoshkhui
- Allergy Research Center Mashhad University of Medical Sciences Mashhad Iran
- Sahar Rastgoo
- Department of Allergy and Immunology Mashhad University of Medical Sciences Mashhad Iran
- Roberta F. J. Criado
- Department of Dermatology Faculdade de Medicina do ABC São Paulo Brazil
- Mohamed Abuzakouk
- Allergy and Immunology Department Cleveland Clinic Abu Dhabi Abu Dhabi UAE
- Deepa Grandon
- Allergy and Immunology Department Cleveland Clinic Abu Dhabi Abu Dhabi UAE
- Martijn B. A. Van Doorn
- Department of Dermatology Erasmus MC Rotterdam The Netherlands
- Solange Oliveira Rodrigues Valle
- Department of Internal Medicine Hospital Universitário Clementino Fraga Filho Rio de Janeiro Brazil
- Eduardo Magalhães De Souza Lima
- Faculty of Science and Health of Juiz de Fora ‐ SUPREMA ‐ Minas Gerais Rio de Janeiro Brazil
- Simon Francis Thomsen
- Department of Dermatology Bispebjerg Hospital University of Copenhagen, Biomedical Sciences Copenhagen Denmark
- German D. Ramón
- Instituto de Alergia e Inmunología del Sur, Bahía Blanca Buenos Aires Argentina
- Edgar E. Matos Benavides
- Centro de Referencia de Alergia Asma e Inmunología ‐ Instituto Nacional del Niño Lima Peru
- Andrea Bauer
- Department of Dermatology University Allergy Center University Hospital Carl Gustav Carus Technical University Dresden Germany
- Ana M. Giménez‐Arnau
- Department of Dermatology Hospital del Mar IMIM, Universitat Autònoma Barcelona Spain
- Emek Kocatürk
- Department of Dermatology Koç University School of Medicine Istanbul Turkey
- Carole Guillet
- Department of Dermatology University Hospital Zurich Zurich Switzerland
- Jose Ignacio Larco
- Allergy Department Clinica San Felipe Lima Peru
- Zuo‐Tao Zhao
- Department of Dermatology and Venereology Peking University First Hospital Beijing China
- Michael Makris
- Allergy Unit 2nd Department of Dermatology and Venereology National and Kapodistrian University of Athens “Attikon” University Hospital Athens Greece
- Carla Ritchie
- Allergy Division Hospital Italiano de Buenos Aires Buenos Aires Argentina
- Paraskevi Xepapadaki
- Allergy Department 2nd Pediatric Clinic National and Kapodistrian University of Athens Athens Greece
- Luis Felipe Ensina
- Federal University of São Paulo São Paulo Brazil
- Sofia Cherrez
- Respiralab Respiralab Research Group Guayaquil Ecuador
- Marcus Maurer
- Institute for Allergology, Charité ‐ Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany
- DOI
- https://doi.org/10.1002/clt2.12089
- Journal volume & issue
-
Vol. 11,
no. 10
pp. n/a – n/a
Abstract
Abstract Background Information/communication technologies such as mobile phone applications (apps) would enable chronic urticaria (CU) patients to self‐evaluate their disease activity and control. Yet, recently Antó et al (2021) reported a global paucity of such apps for patients with CU. In this analysis, we assessed patient interest in using apps to monitor CU disease activity and control using questions from the chronic urticaria information and communication technologies (CURICT) study. Methods The methodology for CURICT has been reported. Briefly, a 23‐item questionnaire was completed by 1841 CU patients from 17 UCAREs across 17 countries. Here, we analyzed patient responses to the CURICT questions on the use of apps for urticaria‐related purposes. Results As previously published, the majority of respondents had chronic spontaneous urticaria (CSU; 63%; 18% chronic inducible urticaria (CIndU) [CIndu]; 19% with both), were female (70%) and in urban areas (75%). Over half of patients were very/extremely interested in an app to monitor disease activity (51%) and control (53%), while only ∼1/10 were not. Patients with both urticaria types versus those with CSU only (odds ratio [OR], 1.36 [1.03–1.79]) and females versus males (OR [95% CI], 1.47 [1.17–1.85]) were more likely to be very to extremely interested in an app to assess disease control. Conclusions Overall, half of the patients with CU were very to extremely interested in using an app to assess their disease activity and control. Development of well‐designed apps, specific to disease types (CSU, CIndU, CSU + CIndU, etc), validated by experts across platforms would help improve the management and possibly outcomes of CU treatment while providing important patient information to be used in future research.
Keywords